Banco Bilbao Vizcaya Argentaria S.A. Has $26.03 Million Stock Holdings in Intuitive Surgical, Inc. $ISRG

Banco Bilbao Vizcaya Argentaria S.A. reduced its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 45,903 shares of the medical equipment provider’s stock after selling 2,071 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Intuitive Surgical were worth $26,031,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in the business. State Street Corp lifted its stake in shares of Intuitive Surgical by 1.0% during the 4th quarter. State Street Corp now owns 15,701,591 shares of the medical equipment provider’s stock worth $8,892,753,000 after buying an additional 162,264 shares during the last quarter. Capital World Investors boosted its holdings in Intuitive Surgical by 1.7% in the 4th quarter. Capital World Investors now owns 7,856,018 shares of the medical equipment provider’s stock valued at $4,449,491,000 after purchasing an additional 127,526 shares during the period. Norges Bank acquired a new position in shares of Intuitive Surgical during the 4th quarter worth approximately $2,856,987,000. Fisher Asset Management LLC increased its holdings in shares of Intuitive Surgical by 1.1% during the third quarter. Fisher Asset Management LLC now owns 3,889,439 shares of the medical equipment provider’s stock worth $1,739,475,000 after purchasing an additional 40,702 shares during the period. Finally, Amundi raised its position in shares of Intuitive Surgical by 29.7% in the third quarter. Amundi now owns 3,227,472 shares of the medical equipment provider’s stock valued at $1,451,362,000 after buying an additional 739,444 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Gary Loeb sold 400 shares of the firm’s stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $424.14, for a total transaction of $169,656.00. Following the completion of the transaction, the executive vice president owned 5,720 shares of the company’s stock, valued at approximately $2,426,080.80. This trade represents a 6.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Iman Jeddi sold 5,625 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $420.55, for a total value of $2,365,593.75. Following the completion of the sale, the senior vice president owned 6,463 shares of the company’s stock, valued at $2,718,014.65. The trade was a 46.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 7,169 shares of company stock valued at $3,059,135 in the last 90 days. Corporate insiders own 0.60% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on ISRG shares. HSBC reduced their price target on Intuitive Surgical from $653.00 to $604.00 and set a “buy” rating on the stock in a research report on Wednesday, April 22nd. Citigroup upgraded Intuitive Surgical from a “neutral” rating to a “buy” rating and set a $590.00 target price for the company in a research report on Wednesday, March 11th. Piper Sandler restated an “overweight” rating and issued a $580.00 price target on shares of Intuitive Surgical in a research report on Tuesday, June 2nd. Mizuho set a $525.00 price target on Intuitive Surgical and gave the company a “neutral” rating in a research note on Monday, April 13th. Finally, The Goldman Sachs Group set a $558.00 price objective on shares of Intuitive Surgical in a research report on Wednesday, May 27th. Nineteen analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $573.42.

Intuitive Surgical Stock Down 3.6%

Intuitive Surgical stock opened at $402.18 on Thursday. The stock has a market cap of $142.44 billion, a PE ratio of 48.75, a P/E/G ratio of 3.39 and a beta of 1.46. Intuitive Surgical, Inc. has a 12-month low of $396.68 and a 12-month high of $603.88. The business’s 50-day moving average price is $440.46 and its two-hundred day moving average price is $492.22.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 EPS for the quarter, topping analysts’ consensus estimates of $2.08 by $0.42. The firm had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.62 billion. Intuitive Surgical had a net margin of 28.15% and a return on equity of 15.98%. The business’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.81 earnings per share. As a group, analysts expect that Intuitive Surgical, Inc. will post 8.57 earnings per share for the current year.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.